Stroke treatment with intra-arterial thrombolytics, such as plasminogen activators still remain the mainstay intervention per se or in combination with mechanical thrombectomy 3, which must be further evolved to decrease the mortality rate of the disease and to ameliorate the consequences for the stroke survivors 2. The gene discussed is PLG; the disease is stroke disorder.